TESSERACT MEDICAL RESEARCH - Key Persons
Al Czap, holder of three prior patents, has developed this new fourth patent pending delivery method. Al has been an industry leader and educator in preventive medicine since founding Thorne Research in 1984. He was the first to recognize the need for hypoallergenic ingredients and the first to devise methods of manufacture to deliver hypoallergenic products to an underserved patient population. Prior to his innovation and industry changing manufacturing techniques, patients with severely impaired immune and digestive system or patients compromised by environmental exposure had no place to turn. Al made products that were truly hypoallergenic and set the standard for treatment of all patients with nutritional medicine.
In 1996 Al began publishing the highly acclaimed, peer reviewed, indexed medical journal, Alternative Medicine Review. For 17 years, AMR was considered by preventive medical physicians to be the most authoritative reference and educational journal in its field. He continued publication of AMR for two years after his sale of Thorne to an investor group in 2010.
After experimenting unsuccessfully with semi-retirement, Al was drawn back to doing research through his new company, Czap R&D. Al has always been frustrated by the awareness that many important patient medical issues have not been effectively solved by the healthcare ecosystem. In particular, he has spent considerable time questioning assumptions taken for granted by the academic community that often undermine effective exploration of alternatives.
In 2015 Al's exploration of drug delivery methodologies led him to the revelation that the perceived limitations of nutrient bioavailability could be shattered with an inventive and optimized approach to nano-level delivery. His resulting technological discoveries and patent filing form the backbone of what will quickly become the leading medical company in the industry, Tesseract Medical Research, LLC.
Dr. Richard Frye is a Child Neurologist with expertise in neurodevelopmental and neurometabolic disorders. He received an MD and PhD in Physiology and Biophysics from Georgetown University. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children's Hospital Boston and Fellowship in Psychology at Boston University. He also received a Masters in Biomedical Science and Biostatistics from Drexel University. He holds board certifications in Pediatrics, and in Neurology with Special Competence in Child Neurology. Dr. Frye is a national leader in autism research. He has authored over 150 peer-reviewed publications and book chapters, and serves on several editorial boards.
He has lead several clinical studies on children with autism spectrum disorder (ASD), including studies focusing on defining the clinical, behavioral, cognitive, genetic and metabolic characteristics of children with ASD. He has conducted several clinical trials demonstrating the efficacy of safe and novel treatments that target underlying physiological abnormalities in children with ASD. Recent research studies have investigated the connections between disruptions in the gut microbiome and neurodevelopmental disorders, particularly through the microbiome's production of short chain fatty acids such as propionate and butyrate.
Dr. Richard Frye is a Child Neurologist with expertise in neurodevelopmental and neurometabolic disorders. He received an MD and PhD in Physiology and Biophysics from Georgetown University. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children's Hospital Boston and Fellowship in Psychology at Boston University… MORE
Job Titles:
- Advisor
- Director of Research and Innovation for Aces Health
John Slattery is the Director of Research and Innovation for Aces Health. Prior to his time at Aces, John worked in Academia at UPenn and Arkansas Children's Hospital/UAMS. He has conducted systems level Neuroscience (fMRI and DTI, perfusion imaging) investigating neural correlates of attention networks after a traumatic brain injury or stroke. Mr. Slattery has a few publications on this work. After his stint at Penn, John transitioned to clinical research on neurodevelopmental disorders (particularly Autism Spectrum Disorders (ASD). During this time, he
completed the first DBPC trial in ASD in which a medical intervention improved core and associated ASD symptoms and through biomarkers could predict which children would respond based on a biomarker in their body. It was billed the first positive precision medicine initiative in psychiatry. John has authored or co-authored over 35 publications based on our ASD work related to oxidative stress, mitochondrial dysfunction, enteric ecosystem disruption, metabolism, and immune dysfunction and 1 book chapter on the usage of N-acetylcsytine in Neuropsychiatry. He sits on a few scientific advisory boards and is considered an expert in systems level biology in relation to CNS disorders.
What motivated John to join Aces Health was the need for a digital health ecosystem to take disparate data sources and have all data that can be collected from a patient (genetic/epigenetic, exposome, microbiome, proteomics, metabolomics, lifestyle, ePRO, eCOA, EHRs, etc) all within a unified and centralized platform.
John's speciality is anything clinical trial design particularly in leveraging Health initiatives into CNS related disorders.
John Slattery is the Director of Research and Innovation for Aces Health. Prior to his time at Aces, John worked in Academia at UPenn and Arkansas Children's Hospital/UAMS. He has conducted systems level Neuroscience (fMRI and DTI, perfusion imaging) investigating neural correlates of attention networks after a traumatic brain injury or stroke. Mr. Slattery has a few publications on this work… MORE